GU Cancers 2024 | SECuRE: 67Cu-SAR-bisPSMA, a novel PSMA theranostic, in mCRPC
Geoffrey Johnson, MD, PhD, Mayo Clinic, Rochester, MN, provides an overview of the Phase I/IIa SECuRE trial (NCT04868604) of 67Cu-SAR-bisPSMA, a novel PSMA theranostic consisting of a beta emitter, in patients with metastatic castrate-resistant prostate cancer (mCRPC). The investigational agent had promising efficacy with minimal toxicity, and is similar to 177Lu-PSMA-617. The peptide component of 67Cu-SAR-bisPSMA additionally enables enhanced imaging capabilities, as seen in the PROPELLER trial (NCT04839367). This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
Yeah. The SECuRE trial is for advanced castrate resistant prostate cancer. They could have had or not had chemotherapy. And right now it’s in dose escalation. So it’s a Phase I/IIa trial. And the concept is to look at whether or not we’re going to see significant toxicity as the main thing and then expand out into a Phase II. Luckily in the SECuRE trial, the SAR-bisPSMA has already shown some surprisingly strong efficacy even in the early Phase I dose escalation without significant toxicity...
Yeah. The SECuRE trial is for advanced castrate resistant prostate cancer. They could have had or not had chemotherapy. And right now it’s in dose escalation. So it’s a Phase I/IIa trial. And the concept is to look at whether or not we’re going to see significant toxicity as the main thing and then expand out into a Phase II. Luckily in the SECuRE trial, the SAR-bisPSMA has already shown some surprisingly strong efficacy even in the early Phase I dose escalation without significant toxicity. So we’re pretty excited that this therapy will have a role in the field of maybe 20 different PSMA targeted radiopharmaceuticals. It is a beta emitter, and so that would compare similarly to say, Plucivto. So from Novartis that’s out there and I think it’s going to have a role to play potentially. We’ll see as the efficacy gets looked at in more deeply, but potentially head to head with what’s out there in the market in the beta emitters. The alpha emitters will probably take longer to develop, of which there are many. And then there are antibodies where the SECuRE trial is a peptide, it’s a PSMA peptide agent, so a small molecule with rapid clearance. But one of the advantages of this is, as we saw with the imaging, because we can image where the drug goes and we know therefore that’s where the therapy goes, like in the PROPELLER trial, that this has probably the best binding to tumors that we see as we can see on the imaging with PET scans.
Read more...
